Compare PXED & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | JANX |
|---|---|---|
| Founded | 1976 | 2017 |
| Country | United States | United States |
| Employees | 3400 | 108 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 847.1M |
| IPO Year | N/A | 2021 |
| Metric | PXED | JANX |
|---|---|---|
| Price | $29.00 | $14.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $44.29 | ★ $47.00 |
| AVG Volume (30 Days) | 79.5K | ★ 870.0K |
| Earning Date | 04-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.49 | N/A |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.52 | $12.12 |
| 52 Week High | $38.19 | $35.34 |
| Indicator | PXED | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 43.52 |
| Support Level | $28.60 | $13.88 |
| Resistance Level | $30.85 | $14.44 |
| Average True Range (ATR) | 1.40 | 0.55 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 46.88 | 37.35 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.